|
PRODUCT PIPELINE
Icagen is conducting clinical and preclinical studies in its core focus areas, which include the following:
ICA-105665 has completed two Phase I clinical studies. Proof of concept trials
in patients with photosensitive Epilepsy and in volunteers subject to mildly
painful stimuli are ongoing. ICA-105665 is a novel opener of the KCNQ ion
channel which in preclinical studies has demonstrated a broad spectrum of
activity in models of epilepsy. In addition, ICA-105665 has also demonstrated
activity in certain models of pain.
Senicapoc, formerly known as ICA-17043, has recently completed two proof of
concept clinical trials for the treatment of asthma. In all previous clinical
studies senicapoc has demonstrated a favorable safety and tolerability profile.
While the Company does not plan to pursue further clinical development of
senicapoc for asthma, this program is a candidate for partnering or
outlicensing
Icagen has a broad research effort directed at novel ion channel targets for
pain control. In August, 2007, Icagen entered into a collaboration with
Pfizer for the discovery and development of novel pharmaceuticals directed
against three sodium channel targets. In addition, Icagen is pursuing research
directed at multiple ion channel targets in its pain control program.
Icagen has a broad research effort directed at novel ion channel targets for
inflammatory disorders. As a result, Icagen has identified several ion channel
targets that are expressed at high levels in some immune system cells and
that may play an important role in modulating the inflammatory response.
Icagen has discovered compounds that are active in vitro against some of
these targets, leading to decreases in calcium entry into immune system
cells, decreases in immune system cell proliferation, decreases in immune
system cell migration into tissues and other measures of inflammatory
responses. Icagen has also demonstrated effects of our compounds in
animal models of inflammatory diseases.
In addition to the areas noted above, Icagen is continuing to explore the human ion channel genome, for which it has completed the cloning of all human ion channel genes, to identify new therapeutic opportunities.
|
